|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Immunohistochemical expression of Ki-67, Cyclin D1, p16INK4a, and Survivin as a predictive tool for recurrence and progression-free survival in papillary urothelial bladder cancer pTa / pT1 G2 (WHO 1973).
|
30446453 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Notably, the upregulation of CCND1 impaired the effect of MALAT1 inhibition on BC cell proliferation and migration.
|
30387807 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
The NPL4/DXO/cyclin D1 axis exert crucial role in BC cell growth and is associated with prognosis and may represent a potential therapeutic target for BC.
|
31164795 |
2019 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Decreased c-Myc mRNA Stability via the MicroRNA 141-3p/AUF1 Axis Is Crucial for p63α Inhibition of Cyclin D1 Gene Transcription and Bladder Cancer Cell Tumorigenicity.
|
30104251 |
2018 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Our data from bioinformatic and luciferase reporter gene assays identified that miR-5195-3p targeted the mRNA 3'-UTR of Krüppel-like factor 5 (KLF5), which is a proven proto-oncogene in bladder cancer. miR-5195-3p sharply reduced KLF5 expression and suppressed the expression or activation of its several downstream genes that are kinases improving cell survival or promoting cell cycle regulators, including ERK1/2, VEGFA, and cyclin D1.
|
28109084 |
2017 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Suppression of PHLPP2 or FOXO1 by miR-135a, consisted with dysregulation of p21, p27, Cyclin D1 and Ki67, play important roles in bladder cancer progression.
|
25888950 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The knock-down of miR-576-3p significantly promoted the proliferation of bladder cancer cells by accelerating the progression of cell cycle and increased the expression of cyclin D1.
|
25556372 |
2015 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The aim of this meta-analysis is to generate large-scale evidence to determine the degree to which common Cyclin D1 (CCND1) G870A (dbSNP: rs603965) and xeroderma pigmentosum group C (XPC) Ala499Val (dbSNP: rs2228000) polymorphisms are associated with susceptibility to bladder cancer.
|
24264314 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
When stratifying for the race, our analysis suggested that CCND1 G870A was associated with bladder cancer risk in Asians when using homogeneous codominant (OR = 1.72, 95% CI 1.34-2.20, P < 0.0001), recessive (OR = 1.46, 95% CI 1.21-1.77, P < 0.0001), dominant (OR = 1.36, 95% CI 1.10-1.69, P = 0.004), and allelic models (OR = 1.30, 95% CI 1.15-1.47, P < 0.0001) to analyze the data.
|
23893383 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In the present study, amplification status of CCND1 and expression of CyclinD1 were evaluated by fluorescence in situ hybridization and immunohistochemistry on tissue microarrays from 152 lymph node-positive urothelial bladder cancers (one sample each from the center and invasion front of the primary tumors, two samples per corresponding lymph node metastasis) treated by cystectomy and lymphadenectomy.
|
23887292 |
2014 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Tissue microarrays containing bladder cancer specimens (n=212) and adjacent normal bladder tissues (n=131) were immunostained using an antibody against cyclin D1.
|
24324055 |
2013 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The genotype analysis results showed that CCND1 GG genotype was associated with a lower risk overall in urothelial (P = 0.008, OR = 0.44, 95% CI = 0.24-0.81) and bladder cancer patients (P = 0.008, OR = 0.34, 95% CI = 0.15-0.76) than those of the AA genotype.
|
21789902 |
2011 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Further statistical analysis revealed significant associations between increased p21 levels and bladder cancer patients with no exposure to chemicals (p=0.048), as well as with patients with no artificial sweetener intake (p=0.012), and between increased Cyclin D1 levels and study subjects with no artificial sweetener intake (p=0.012).
|
21766505 |
2011 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cell cycle (MDM2 and Cyclin D1) and apoptotic (Fas) genes that are differentially expressed in urinary bladder cancer (UBC) were investigated with the susceptibility to UBC in northern India.
|
20380574 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The CCND1 G870A polymorphism may be a marker for the development of bladder cancer in Chinese populations.
|
20575692 |
2010 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
To test the hypothesis that common sequence variants in the cell cycle control pathway may affect bladder cancer susceptibility, the effects of a panel of 10 potential functional single nucleotide polymorphisms (SNPs) from 7 cell cycle control genes, P53, P21, P27, CDK4, CDK6, CCND1, and STK15, were evaluated on bladder cancer risk in a case-control study of 696 bladder cancer cases and 629 healthy controls.
|
18361427 |
2008 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Cyclin D1 over-expression appears to be an early event in bladder cancer and might explain bilharzial associated bladder carcinogenesis.
|
15590562 |
2004 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Thus, we concluded that 9p deletions and translocations of chromosome 11, especially at 9p21 and CCND1, are associated with bladder cancer.
|
15390184 |
2004 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Although CCND1 polymorphism is not able to serve as a prognostic marker for bladder cancer, the CCND1 variant A allele may recessively increase the risk of carcinoma in situ incidence in patients with superficial bladder cancer.
|
15245939 |
2004 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, the amplification frequency decreased with increasing genomic distance from CCND1, suggesting that, among the genes examined, CCND1 is the major target gene in the 11q13 amplicon in bladder cancer.
|
14648664 |
2003 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
We conducted a population-based case-control study of incidence of bladder cancer among non-Hispanic whites in Los Angeles County to examine the relationship between CCND1 870A-->G genotypes and bladder cancer risk.
|
12896908 |
2003 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In bladder cancers with beta-catenin mutations copy numbers of the c-myc and cyclin D1 genes did not amplify.
|
12394763 |
2002 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Cyclin D1 gene polymorphism is associated with an increased risk of urinary bladder cancer.
|
11872630 |
2002 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We aimed to investigate the expression of p16 and cyclin D1 genes in order to evaluate their clinical significance in bladder cancer.
|
12372886 |
2002 |
|
Malignant neoplasm of urinary bladder
|
0.100 |
Biomarker
|
disease |
BEFREE |
Amplification of CCND1 or alterations in c-myc/CCND1 early in bladder cancer may have clinical relevance in promoting and predicting progression to detrusor-muscle-invasive transitional cell carcinoma.
|
12237776 |
2002 |